Background
Methods
Study population
CMR protocol
T1-Mapping analysis
Statistical analysis
Sample size calculations for future studies using ShMOLLI native T1-mapping
Results
Subject characteristics
n | Age (years) | Male (n) | BMI (kg/m2) | HR (bpm) | LVEF (%) | LV mass index (g/m2) | LV Wallmin
(mm) | LV Wallmax
(mm) | |
---|---|---|---|---|---|---|---|---|---|
Patients with normal CMR | 70 | 48 ± 17 | 45 | 24 ± 3 | 65 ± 13 | 66 ± 9 | 56 ± 14 | 7 ± 1 | 10 ± 2 |
Cardiac Amyloidosis (AL) | 32 | 73 ± 11 | 11 | 28 ± 5 | 73 ± 13 | 55 ± 15a
| 111 ± 32 | 12 ± 4 | 18 ± 3a
|
Cardiac Amyloidosis (ATTR) | 22 | 75 ± 13 | 14 | 26 ± 4 | 79 ± 19 | 53 ± 14 | 120 ± 16 | 12 ± 3 | 20 ± 5 |
Anderson-Fabry diseaseb
| 21 | 50 ± 17 | 20 | 27 ± 5 | 62 ± 14 | 60 ± 15 | 62 ± 25 | 8 ± 2 | 13 ± 5 |
Aortic Stenosis | 24 | 63 ± 18 | 19 | 29 ± 7 | 73 ± 13 | 62 ± 13 | 83 ± 23 | 9 ± 3 | 14 ± 3 |
Atrial Fibrillationb
| 23 | 66 ± 11 | 18 | 28 ± 4 | 89 ± 19 | 50 ± 13a
| 61 ± 13 | 7 ± 1 | 11 ± 2 |
Chronic CAD | 309 | 62 ± 12 | 193 | 28 ± 5 | 69 ± 14 | 50 ± 16a
| 74 ± 23 | 7 ± 2 | 12 ± 3 |
Dilated Cardiomyopathy | 151 | 60 ± 15 | 98 | 27 ± 7 | 72 ± 15 | 35 ± 14a
| 81 ± 29 | 5 ± 2a
| 8 ± 2 |
Hypertrophic Cardiomyopathy | 185 | 56 ± 15 | 138 | 29 ± 11 | 68 ± 12 | 69 ± 12 | 88 ± 33 | 9 ± 3 | 19 ± 4a
|
Hypertension | 59 | 62 ± 14 | 42 | 29 ± 5 | 68 ± 15 | 61 ± 16 | 83 ± 38 | 9 ± 2 | 14 ± 3 |
Cardiac Iron-Overloadb
| 23 | 53 ± 21 | 17 | 23 ± 9 | 77 ± 14 | 65 ± 13 | 56 ± 27 | 7 ± 2 | 14 ± 3 |
Myocarditis (acute) | 146 | 41 ± 12a
| 68 | 27 ± 5 | 75 ± 13 | 58 ± 13 | 69 ± 18 | 8 ± 2 | 12 ± 2 |
Myocarditis (previous) | 93 | 47 ± 17 | 72 | 27 ± 4 | 69 ± 14 | 61 ± 10 | 62 ± 17 | 7 ± 1 | 11 ± 2 |
Obesity | 38 | 53 ± 15 | 22 | 35 ± 4a
| 70 ± 14 | 60 ± 10 | 60 ± 21 | 7 ± 1 | 10 ± 2 |
Pheochromocytoma | 29 | 50 ± 14 | 14 | 25 ± 6 | 71 ± 29 | 65 ± 10 | 57 ± 12 | 8 ± 1 | 10 ± 1 |
Cardiac Sarcoidosis | 21 | 59 ± 9 | 10 | 28 ± 6 | 74 ± 13 | 60 ± 14 | 64 ± 20 | 8 ± 2 | 13 ± 3 |
Takotsubo cardiomyopathy | 45 | 64 ± 12 | 35 | 25 ± 5 | 74 ± 18 | 60 ± 15 | 58 ± 17 | 8 ± 1 | 11 ± 3 |
Normative native T1 ranges in cardiovascular disease and norm
Native T1 [ms] | Reference myocardium | LGE+ or RWMA+ myocardium |
---|---|---|
Patients with normal CMR | 938 ± 21 | – |
Cardiac Amyloidosis (AL) | – | 1158 ± 75 |
Cardiac Amyloidosis (ATTR) | 1002 ± 63 | 1061 ± 29 |
Anderson-Fabry Diseasec
| 863 ± 23 | 902 ± 17 |
Aortic Stenosis | 952 ± 20 | 1019 ± 23a
|
Atrial Fibrillationc
| 945 ± 25 | 1010 ± 54 |
Chronic CAD | 951 ± 33 | 1078 ± 94a
|
Dilated Cardiomyopathy | 945 ± 27 | 1038 ± 38a
|
Hypertrophic Cardiomyopathy | 932 ± 81 | 1041 ± 86a
|
Hypertension | 944 ± 24 | 1022 ± 43a
|
Cardiac Iron-Overloadc
| 795 ± 58 | – |
Myocarditis (acute) | 947 ± 39 | 1058 ± 74a
|
Myocarditis (previous) | 941 ± 36 | 1026 ± 47a
|
Musculo-dystrophy | 935 ± 23 | 1006 ± 10a
|
Obesity | 936 ± 22 | 1031 ± 28a
|
Pheochromocytoma | 939 ± 24 | 1006 ± 20a
|
Cardiac Sarcoidosis | 934 ± 47 | 1030 ± 53a
|
Takotsubo Cardiomyopathyb
| 988 ± 41 | 1093 ± 64a
|
Sample size calculations
Departure of focally abnormal myocardium from reference myocardium (within subjects) | Departure of reference myocardium from healthy myocardium [19] (between groups) | |||
---|---|---|---|---|
Cohen-d | Paired, n> | Cohen-d | Unpaired, n> | |
Patients with normal CMR | N/A | N/A | 0.14 | 1604 |
Cardiac Amyloidosis (AL) | 4.58 | 2 | – | – |
Cardiac Amyloidosis (ATTR) | 3.91 | 4 | 1.28 | 9 |
Aortic Stenosis | 3.39 | 6 | 0.68 | 146 |
Takotsubo Cardiomyopathy | 3.33 | 6 | 1.06 | 32 |
Dilated Cardiomyopathy | 3.09 | 6 | 0.56 | 104 |
Pheochromocytoma | 3.02 | 6 | 0.09 | 3880 |
Myocarditis (acute) | 2.92 | 6 | 0.52 | 120 |
Obesity | 2.81 | 8 | 0.21 | 716 |
Hypertension | 2.36 | 8 | 0.57 | 100 |
Myocarditis(previous) | 2.30 | 10 | 0.0 | N/A |
Cardiac Sarcoidosis | 2.28 | 10 | 0.0 | N/A |
Cardiac Iron-Overloada
| 2.06 | 10 | 13.30 | 4 |
Chronic CAD | 2.06 | 10 | 0.47 | 146 |
Hypertrophic Cardiomyopathy | 1.59 | 16 | 0.15 | 1398 |
Atrial Fibrillationa
| 1.47 | 18 | 0.29 | 376 |
Anderson-Fabry Diseasea
| 0.82 | 50 | 2.81 | 8 |